Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent Weight Gain While Taking Antipsychotic Medications (GRATITUDE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03818256
Recruitment Status : Recruiting
First Posted : January 28, 2019
Last Update Posted : November 8, 2019
Sponsor:
Information provided by (Responsible Party):
Corcept Therapeutics

Brief Summary:
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant in obese adult with schizophrenia treated with antipsychotic medications.

Condition or disease Intervention/treatment Phase
Antipsychotic-induced Weight Gain (AIWG) Drug: Miricorilant Phase 2

Detailed Description:

This is a randomized, double-blind, placebo-controlled study that will assess the safety, efficacy, and PK of miricorilant in obese patients with schizophrenia who are currently taking olanzapine, risperidone, or quetiapine.

Patients who meet the criteria for the Study CORT118335-876 will be randomized on Day 1 to receive 600 mg miricorilant or placebo for 12 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: Double Blind
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent Weight Gain While Taking Antipsychotic Medications (GRATITUDE)
Actual Study Start Date : October 31, 2019
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : November 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CORT118335- 600 mg
Patients who meet the entry criteria for the Study CORT118335-876 will be randomized to receive 600 mg miricorilant for 12 weeks.
Drug: Miricorilant
Miricorilant 600mg

Placebo Comparator: Placebo
Patients who meet the entry criteria for the Study CORT118335-876 will be randomized to receive placebo for 12 weeks.
Drug: Miricorilant
Placebo tablets for once daily oral dosing




Primary Outcome Measures :
  1. Change from baseline in body weight at Week 12 for 600 mg miricorilant versus placebo [ Time Frame: Baseline Day 1 to Week 12 ]
  2. Incidence of adverse events (AEs), serious AEs (SAEs), and AEs leading to early discontinuation [ Time Frame: Up to week 16 ]
  3. Changes from baseline in hematology at Week 12 [ Time Frame: Baseline Day 1 to week 12 ]
  4. Changes from baseline in chemistry panel at Week 12 [ Time Frame: Baseline Day 1 to week 12 ]

Secondary Outcome Measures :
  1. Percentage of patients achieving more than or equal to 5% weight loss [ Time Frame: Baseline Day 1 to week 12 ]
    Percentage of patients achieving more than or equal to 5% weight loss for 600 mg miricorilant versus placebo

  2. Change from baseline in Homeostatic model assessment for insulin resistance (HOMA-IR) at Week 12 [ Time Frame: Baseline Day 1 to week 12 ]
    Change in insulin resistance (HOMA-IR) for 600 mg miricorilant versus placebo

  3. Change from baseline in waist-to-hip ratio at Week 12 [ Time Frame: Baseline Day1 to week 12 ]
    600 mg Miricorilant versus placebo



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have a diagnosis of schizophrenia
  • Are currently taking olanzapine, risperidone, or quetiapine and must have documented weight gain while on these medications
  • Must be on a stable dose of medication for 1 month prior to screening
  • Are able to successfully complete placebo tablet swallow test
  • Have a BMI ≥30 kg/m2

Exclusion Criteria:

  • Have a history of a medical condition affecting body weight (e.g., poorly controlled hyper- or hypothyroidism; eating disorder such as anorexia, bulimia, or binge eating; or polycystic ovary syndrome).
  • Have poorly controlled diabetes mellitus
  • Have poorly controlled hypertension
  • Have a history of hypotension
  • Have a history of orthostatic hypotension

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03818256


Contacts
Layout table for location contacts
Contact: Clinical Trial Lead 650-688-8806 study876ctgov@corcept.com

Locations
Layout table for location information
United States, Arkansas
Site 143 Not yet recruiting
Bentonville, Arkansas, United States, 72712
United States, California
Site 153 Not yet recruiting
Culver City, California, United States, 90230
Site 134 Recruiting
Lemon Grove, California, United States, 91945
Site 126 Not yet recruiting
Oakland, California, United States, 94607
Site 150 Not yet recruiting
Stanford, California, United States, 94304
United States, Florida
Site 144 Not yet recruiting
Miami, Florida, United States, 33161
United States, Georgia
Site 145 Not yet recruiting
Atlanta, Georgia, United States, 30331
United States, Illinois
Site 140 Not yet recruiting
Lincolnwood, Illinois, United States, 60712
United States, Kansas
Site 146 Not yet recruiting
Wichita, Kansas, United States, 67214
United States, Maryland
Site 138 Recruiting
Glen Burnie, Maryland, United States, 20161
United States, Nevada
Site 151 Not yet recruiting
Las Vegas, Nevada, United States, 89102
United States, Ohio
Site 107 Recruiting
Dayton, Ohio, United States, 45417
United States, South Carolina
Site 152 Not yet recruiting
Charleston, South Carolina, United States, 29407
United States, Utah
Site 139 Recruiting
Salt Lake City, Utah, United States, 84105
United States, Washington
Site 137 Not yet recruiting
Bellevue, Washington, United States, 98007
Sponsors and Collaborators
Corcept Therapeutics
Investigators
Layout table for investigator information
Study Director: Ada Lee, MD Corcept Therapeutics

Layout table for additonal information
Responsible Party: Corcept Therapeutics
ClinicalTrials.gov Identifier: NCT03818256    
Other Study ID Numbers: CORT118335-876
First Posted: January 28, 2019    Key Record Dates
Last Update Posted: November 8, 2019
Last Verified: November 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Corcept Therapeutics:
Antipsychotic-induced weight gain (AIWG)
Obesity
Weight Gain
Mental disorders
Schizophrenia
Risperidone
Quetiapine
Olanzapine
Additional relevant MeSH terms:
Layout table for MeSH terms
Body Weight
Weight Gain
Schizophrenia
Signs and Symptoms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Body Weight Changes
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs